Search

everythinglearnresearchcommunity

for

Search:↓

Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.

Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.

Caregivers of chronic skin disease patients face significant burdens that harm their quality of life.

Alopecia areata negatively affects the self-esteem and quality of life of children and teens.

Alopecia areata greatly affects people's life quality, mental health, and work life.

Alopecia areata significantly worsens quality of life in children, causing embarrassment and social issues.

Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.

Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.

Vitiligo causes significant emotional stress in Africa, the Middle East, and Latin America, with limited treatment options available.

The DLQI is a key tool for measuring quality of life in dermatology.

A plant-based diet and certain probiotics may improve skin health and reduce inflammation.

There is a significant need for better-validated quality of life tools in dermatology.

The Dermatology Life Quality Index is reliable and consistent but needs more diverse participant studies.

Managing inflammation and using vitamins can improve PRP therapy for better hair growth.

Tinea capitis in adults, especially postmenopausal Black women, needs prompt treatment with oral antifungals to avoid scarring.

Skin bacteria help heal wounds and restore healthy skin.

Tinea capitis can affect mental health, but treatment improves both health and well-being.

A thorough skin history and full examination are important for diagnosing and understanding the impact of skin diseases.

The DLQI is reliable but may not fully capture the impact of skin conditions on quality of life, especially in emotional and psychological areas.

Using both DLQI and Skindex-16 together gives a better understanding of quality of life in skin disease patients.

Skin disease activity scores can help decide when skin symptoms no longer affect the quality of life in patients with mild dermatomyositis.

The electronic version of the Dermatology Life Quality Index is as effective as the paper version, with most patients preferring it.

CLASI is a valid tool for assessing skin activity and damage in lupus patients.

The CLASI is a reliable tool for measuring the severity of cutaneous lupus erythematosus.

DLQI is a reasonable quality-of-life measure for alopecia patients, but more research is needed.

All parts of the CLASI-A score are important for assessing skin activity in cutaneous lupus erythematosus.

The CLASI is useful but needs revision to accurately assess all cutaneous lupus erythematosus subtypes.

The Thai version of the Family Dermatology Life Quality Index is a reliable and valid tool for assessing the quality of life of patients' families.

Clq deficiency is linked to systemic lupus erythematosus symptoms.

Excluding alopecia and mucous membrane components from the CLASI-A score reduces its effectiveness in capturing important disease activity.